Skip to main content
TipRanks
Go Ultimate75% OFF

Resonance Health Ltd (RHT) AI Stock Analysis

3 Followers
AU:RHT

Resonance Health Ltd

(ASX:RHT)

Select Model
Rating:66.5Neutral
Price Target:AUD 0.09â–²(8.24% Upside)
Action:downgraded
Date:11/17/26

The score is driven primarily by improving financial performance (profitability and cash flow rebound in 2026, alongside multi-year revenue growth), supported by constructive technical trends with neutral momentum. This is tempered by a relatively high P/E valuation and ongoing historical volatility in earnings/cash flow, which adds execution risk.

Positive Factors
Strong multi-year revenue scalingThe substantial multi-year increase in revenue indicates that Resonance Health is expanding commercial adoption of its imaging-analysis software and related services. Continued scaling can broaden the recurring and usage-based revenue base, support operating leverage, and strengthen the company’s position in quantitative medical imaging.
Negative Factors
Earnings volatilityThe sharp movement between profit and loss indicates that earnings are not yet consistently predictable. Such volatility can make planning and resource allocation more difficult, increase execution risk during the next growth phase, and reduce confidence that the latest profitability improvement will persist through a full business cycle.

Resonance Health Ltd (RHT) vs. iShares MSCI Australia ETF (EWA)

-50%-25%0%25%50%75%100%AU:RHT+73.47%EWA+16.51%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 44.28M
Dividend Yield
―
Average Volume (3M)
626.76K
Price to Earnings (P/E)
26.6
Beta (1Y)
1.71
Revenue Growth
42.25%
EPS Growth
―
Country
Australia
Employees
18
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Resonance Health Ltd Business Overview & Revenue Model

Company Description

Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Middle...

How the Company Makes Money

Resonance Health generates revenue primarily by commercialising its medical imaging software and related services. Key revenue streams include: (1) Software licensing and subscriptions: income from licensing its imaging-analysis software to hospitals...

Resonance Health Ltd Financial Statement Overview

Summary

Improving fundamentals with a material profitability rebound in 2026 (return to positive EBIT and net income) and strong revenue scaling over time, supported by strong gross profit. Offsetting this is notable year-to-year volatility in earnings and cash flow, plus moderately higher leverage than earlier years, which reduces confidence in consistency.

Income Statement

71Positive

Balance Sheet

63Positive

Cash Flow

68Positive
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue15.75M15.75M11.07M8.59M4.40M3.83M
Gross Profit14.80M14.80M11.07M8.59M4.40M3.83M
EBITDA2.48M2.48M-618.63K-382.00K-827.69K-1.34M
Net Income1.51M1.51M-1.73M169.30K-780.00K-1.14M
Balance Sheet
Total Assets18.74M18.74M17.89M20.28M10.98M11.69M
Cash, Cash Equivalents and Short-Term Investments4.85M4.85M2.98M6.85M6.36M6.78M
Total Debt3.81M3.81M3.80M3.70M272.94K268.22K
Total Liabilities7.63M7.63M8.50M9.35M1.05M995.58K
Stockholders Equity11.11M11.11M9.39M10.93M9.94M10.69M
Cash Flow
Free Cash Flow2.79M2.79M805.39K1.01M-624.93K-1.42M
Operating Cash Flow2.88M2.88M1.25M1.39M-157.03K-712.67K
Investing Cash Flow-300.53K-300.53K-4.52M-3.94M-467.90K-704.00K
Financing Cash Flow-597.54K-597.54K-649.26K3.01M-81.97K-107.11K

Resonance Health Ltd Technical Analysis

Technical Analysis SentimentPositive
Last Price0.09

Price Trends

50DMA0.07Positive
100DMA0.06Positive
200DMA0.05Positive

Market Momentum

MACD0.00Negative
RSI52.29Neutral
STOCH52.56Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHT, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.07, and above the 200-day MA of 0.05, indicating a bullish trend. The MACD of 0.00 indicates Negative momentum. The RSI at 52.29 is Neutral, neither overbought nor oversold. The STOCH value of 52.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:RHT.

Resonance Health Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:RHT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:PMEAU:PME76OutperformAUD 21.07B79.3963.19%0.34%22.87%130.30%
AU:RHTAU:RHT67NeutralAUD 47.64M26.5613.72%―42.25%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:SHGAU:SHG50NeutralAUD 66.85M-10.10-57.06%―603.32%10.57%
AU:AYAAU:AYA49NeutralAUD 503.14M-17.59-30.04%―<0.01%2.08%
AU:M7TAU:M7T42NeutralAUD 63.45M-7.11-24.29%―-17.35%-47.29%
AU:BMTAU:BMT40UnderperformAUD 20.08M-1.08-58.13%―2.08%-195.31%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%AU:RHTAU:PMEAU:M7TAU:BMTAU:SHGAU:AYADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:RHT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:RHTResonance Health Ltd0.090.0484.78%
AU:PMEPro Medicus Limited201.66-47.49-19.06%
AU:M7TMach7 Technologies Ltd.0.27-0.06-18.18%
AU:BMTBeamtree Holdings Ltd0.07-0.13-66.00%
AU:SHGSingular Health Group Ltd0.20-0.08-29.31%
AU:AYAArtrya Limited3.060.165.52%

Resonance Health Ltd Corporate Events

Resonance Health Completes Design and Testing of MRI Muscle Endpoint

Nov 10, 2026

Resonance Health has completed the design and testing of an MRI Muscle Endpoint measuring mid-thigh intramuscular fat fraction, intermuscular adipose tissue, muscle volume, fat-free muscle volume and subcutaneous adipose tissue. Its use as an investi...

Resonance Health Adds Shareholder Votes on Placement Shares

Nov 6, 2026

Resonance Health has added two resolutions to its 19 November 2026 annual general meeting agenda, seeking shareholder ratification for the prior issue of 35,621,296 placement shares under Listing Rule 7.1 and 47,712,023 shares under Listing Rule 7.1A...

Resonance Health Completes $6 Million Share Placement

Nov 6, 2026

Resonance Health Ltd completed a placement of 83,333,320 fully paid ordinary shares at $0.072 each to institutional, professional and sophisticated investors, raising approximately $6.0 million.The company confirmed the shares were issued without a d...

Resonance Health Applies to Quote 83.3 Million Shares

Nov 6, 2026

Resonance Health has applied to quote 83,333,320 fully paid ordinary shares on the ASX under the code RHT, with an issue date of November 6, 2026. The securities were issued as part of a transaction previously announced to the market, increasing the...

Resonance Health Appoints Leader for TrialsWest East-Coast Expansion

Nov 3, 2026

Resonance Health, an Australian healthcare company providing clinical-trial site and research services through its TrialsWest network, has appointed an experienced clinical operations executive to lead east-coast site development. The executive start...

Resonance Health Unveils Early MRI Liver Fibrosis Data and Plans Capital Raise

Oct 26, 2026

Resonance Health has presented preliminary data from its extended proof-of-concept clinical study for a non-invasive MRI liver fibrosis device. The investigational technology was assessed in 50 subjects across a broad spectrum of liver conditions, in...

Resonance Health Plans Major Share Placement on ASX

Oct 26, 2026

Resonance Health Ltd has notified the ASX of a proposed issue of up to 83,333,319 ordinary fully paid shares. The securities are to be issued via a placement or similar structure, with a proposed issue date of 9 November 2026, subject to ASX processe...

Resonance Health’s MRI Fibrosis Tool Matches FibroScan, Targets $1.3bn Trial Market

Oct 26, 2026

Resonance Health has reported preliminary extended proof-of-concept results for its FibrosisAssessment MRI-based liver fibrosis software, showing diagnostic accuracy comparable to the widely used FibroScan ultrasound device for significant fibrosis....

Resonance Health Seeks ASX Trading Halt Ahead of Clinical Trial Update and Capital Raising

Oct 22, 2026

Resonance Health Ltd has requested a trading halt in its ordinary shares on the ASX, effective from the start of trading on 23 October 2026. The halt is designed to support the company’s compliance with continuous disclosure rules while it prepares a...

Resonance Health Sets Date and Voting Details for 2026 AGM

Oct 20, 2026

Resonance Health Ltd has scheduled its 2026 Annual General Meeting for 19 November 2026 at the QV1 Building in Perth, Western Australia. The company will not mail physical copies of the Notice of Meeting and Explanatory Statement to shareholders who...

Resonance Health Sets Date to Reveal Key Trial Data on MRI Liver Fibrosis Device

Oct 19, 2026

Resonance Health Ltd, an Australian healthcare technology firm, provides non-invasive MRI-based Software-as-Medical Devices and imaging services that support clinicians and pharmaceutical companies worldwide. Its AI-driven products for liver and card...

Resonance Health Sets AGM Date and Board Nomination Deadline

Sep 29, 2026

Resonance Health Ltd has scheduled its next Annual General Meeting for 19 November 2026, with formal meeting materials to be circulated to shareholders and published via the ASX and the company’s investor website in due course. The company has also s...

Resonance Health Strikes Global Imaging Alliance with Image Analysis Group

Sep 16, 2026

Resonance Health has signed a Strategic Alliance and Master Services Agreement with London-based Image Analysis Group, integrating its quantitative MRI endpoints into IAG’s global imaging clinical research platform. The deal makes Resonance’s SaMD pr...

Resonance Health Files 2026 Corporate Governance Statement with ASX

Aug 31, 2026

Resonance Health Limited has lodged its Appendix 4G and corporate governance statement with the ASX for the financial year ended 30 June 2026, confirming compliance with ASX Listing Rules on governance disclosure. The documents, approved by the board...

Resonance Health Returns to Profit on Record Revenue and Strong Trial Pipeline

Aug 28, 2026

Resonance Health reported a 42% rise in full-year revenue to $15.8 million and returned to profitability with a $1.5 million net profit after tax for the year to 30 June 2026. Normalised EBITDA jumped 83% to $2.6 million at a 16% margin, with all thr...

Resonance Health swings to profit on 42% revenue surge

Aug 27, 2026

Resonance Health Limited reported a strong turnaround for the year ended 30 June 2026, with revenues from ordinary activities rising 42% to $15.75 million and net profit after tax of $1.51 million, compared with a loss of $1.73 million in the prior y...

Resonance Health to Host Investor Webinar on FY26 Results

Aug 19, 2026

Resonance Health will release its full-year financial results for the period to 30 June 2026 on or before 28 August 2026 via the ASX platform. The company’s chief executive officer and chief financial officer will then host a live, interactive webina...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026